Navin Fluorine Q3 Results: Navin Fluorine International announced its results for the quarter ending December 2025 (Q3FY26) on February 2. The company posted a strong set of financial numbers, posting ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention that ...

Shares of Navin Fluorine International slipped on Tuesday after the chemicals major reported earnings for the third quarter of FY26, which more than doubled year on year. At 12:38 pm, Navin Fluorine ...

Sometimes, one piece of good news is enough to change the mood completely. A delayed train finally arriving. An unexpected message. A long-pending result going your way. Markets work much the same way ...

HYDERABAD, (IANS) – In a setback for Jhansi Reddy, a member of the Congress party, her application for Indian citizenship has been denied by Indian authorities. Jhansi Reddy, who holds American ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global ...

Feb 18 (Reuters) - India's Stable Money has raised $25 million in a round led by Peak XV Partners, as the fixed-income investment platform aims to triple its assets under management by year-end to 150 ...

Sumathi Reddy is the "Your Health" columnist at The Wall Street Journal, writing about all things health and medicine. Her columns cover everything from exercise and weight-loss drugs to cannabis and ...

Feb 13, 2026, 4:48 PM IST Navin Fluorine Intl. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript Feb 11, 2026, 12:00 AM IST Navin Fluorine Intl. - Announcement under Regulation 30 ...

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active ...

Citi maintained a sell rating and raised its target price to Rs 5,550 from Rs 4,900. It noted that EBITDA rose 110 per cent year-on-year and margins improved sharply, but said the stock’s recent rally ...